Salvia BioElectronics, a clinical-stage medical device company, has completed an oversubscribed $60 million Series B financing round to advance its neuromodulation therapy for chronic migraine patients. Innovation Industries led the round, with participation from Invest-NL, EIC Fund, and existing investors including Inkef, Panakès Partners, SHS Capital, Dolby Family Ventures, Brabant Development Agency (BOM) and Thuja Capital. The funding will support completion of clinical development and commercial launch preparations for MySalvia Therapy across the United States, Europe and Australia.
The company's proprietary technology addresses a significant unmet medical need in the migraine treatment landscape. Migraine ranks among the leading causes of disability worldwide, generating an estimated $110 billion annually in lost productivity and medical costs across the EU and US. Current treatment options face significant limitations, with the majority of chronic migraine patients discontinuing their medication within the first year. This high dropout rate underscores the urgent need for alternative therapeutic approaches that can provide sustained relief.
MySalvia Therapy represents a paradigm shift in migraine treatment through its patient-centered design and minimally invasive approach. The FDA-designated Breakthrough Device utilizes two ultra-thin implants placed just beneath the skin of the forehead and back of the head. Unlike conventional neuromodulation technologies, Salvia's solution offers reduced surgical complexity, shorter patient recovery time, and a visually discreet profile. The therapy empowers patients with on-demand control through an external wearable device, allowing them to activate targeted stimulation precisely when and where needed with the simple press of a button.
"With the support of this strong investor syndicate, we are empowered to bring MySalvia Therapy to patients in desperate need of new treatment options," said Hubert Martens, founder and CEO of Salvia BioElectronics. "Chronic migraine is not 'just a headache'. It is a debilitating neurological condition that forces people out of their social life, their work, and the life they want to live. Our mission is to restore their freedom. MySalvia Therapy is designed to provide not just relief, but meaningful and lasting impact. We believe people with migraine deserve the opportunity to reclaim their lives. With this funding, we are advancing toward regulatory approval and commercialization, with the ultimate goal of reaching millions of people affected by chronic migraine."
The company is currently evaluating MySalvia Therapy in the RECLAIM study, a multi-center, double-blind, sham-controlled trial in Europe and Australia. Early clinical data suggests potential reductions in both the frequency and intensity of migraine attacks. Additional studies are planned in the US to further evaluate the therapy's safety and effectiveness. Beyond chronic migraine, the technology shows promise for treating cluster headache, another severely painful neurological condition with limited effective treatment options.
"Salvia BioElectronics is redefining the migraine therapy landscape with a bold, patient-centered approach that combines cutting-edge neuromodulation with an elegant, minimally invasive design," said Caaj Greebe, Partner at Innovation Industries. "At Innovation Industries, we invest in breakthrough technologies that have the potential to solve the most pressing real-world challenges and Salvia BioElectronics does exactly that: offering life-changing solutions for millions of people living with chronic migraine. We are excited to partner with the Salvia team as they advance through their clinical development to deliver a meaningful new therapy."
Click here for the original news story.